세계의 지연성 운동장애(TD) 치료제 시장 규모, 점유율, 성장 분석, 치료별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Tardive Dyskinesia Treatment Market Size, Share, and Growth Analysis, By Treatment, By Drugs, By Route of administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1734417
리서치사:SkyQuest
발행일:2025년 05월
페이지 정보:영문 191 Pages
라이선스 & 가격 (부가세 별도)
한글목차
지연성 운동장애(TD) 치료제 세계 시장 규모는 2023년 36억 달러, 2024년 38억 8,000만 달러에서 2032년에는 70억 8,000만 달러로 성장하고, 예측 기간(2025-2032년)의 CAGR은 7.8%를 나타낼 전망입니다.
정신질환의 유병률 증가와 VMAT2 억제제 치료의 발전으로 시장 환경이 크게 변화하고 있습니다. 조기 승인에 대한 규제 당국의 지원이 증가하면서 치료 도입에 유리한 환경이 조성되고 있습니다. 지연성 운동 이상증에 대한 인식이 높아짐에 따라, 특히 의료 인프라가 확대되고 있는 지역에서 이 질환에 대한 적극적인 관리가 이루어지고 있습니다. 제약사들은 연구개발을 강화하기 위해 전략적 파트너십을 적극적으로 추진하고 있습니다. 그러나 시장 개발은 높은 치료비, 현재 치료법에 따른 부작용, 신흥국 지역에서의 낮은 인지도 등의 문제에 직면해 있습니다. 또한, 환자 수가 적어 연구개발 투자가 억제되고 있는 것도 향후 지연성 운동 이상증 치료제의 보급을 저해할 수 있습니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
지연성 운동장애(TD) 치료제 시장 규모 : 치료별&CAGR(2025-2032)
시장 개요
약물
수술
지연성 운동장애(TD) 치료제 시장 규모 : 약물별&CAGR(2025-2032)
시장 개요
항정신병제
VMAT2 억제제
보툴리눔톡신(보톡스)
자연 요법
도파민 감소제
기타
지연성 운동장애(TD) 치료제 시장 규모 : 투여 경로별&CAGR(2025-2032)
시장 개요
경구
주사제
지연성 운동장애(TD) 치료제 시장 규모 : 최종사용자별&CAGR(2025-2032)
시장 개요
병원
홈케어
전문 클리닉
기타
지연성 운동장애(TD) 치료제 시장 규모 : 유통 채널별&CAGR(2025-2032)
시장 개요
병원 약국
소매 약국
기타
지연성 운동장애(TD) 치료제 시장 규모 : 지역별&CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년대비 비교(2022-2024년)
주요 기업 개요
Neurocrine Biosciences, Inc.(U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
H. Lundbeck A/S(Denmark)
AbbVie Inc.(U.S.)
Otsuka Holdings Co., Ltd.(Japan)
Astellas Pharma Inc.(Japan)
Bausch Health Companies Inc.(Canada)
Sumitomo Pharma America, Inc(U.S.)
Reviva Pharmaceuticals Holdings, Inc.(U.S.)
Acadia Pharmaceuticals Inc.(U.S.)
VANDA PHARMACEUTICALS(U.S.)
Eisai Co., Ltd.(Japan)
Zydus Group(India)
Lilly(U.S.)
F. Hoffmann-La Roche Ltd(Switzerland)
Pfizer Inc.(U.S.)
Bristol-Myers Squibb Company(U.S.)
Mallinckrodt(U.S.)
결론과 제안
LSH
영문 목차
영문목차
Global Tardive Dyskinesia Treatment Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.88 billion in 2024 to USD 7.08 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).
Market insights indicate a significant shift in the tardive dyskinesia treatment landscape, driven by the rising prevalence of psychiatric disorders and advancements in VMAT2 inhibitor therapies. The heightened regulatory support for accelerated approvals is fostering a favorable environment for treatment adoption. Increased awareness of tardive dyskinesia, particularly in regions with expanding healthcare infrastructure, is encouraging proactive management of this condition. Pharmaceutical companies are actively pursuing strategic partnerships to enhance research and development efforts. However, the market faces challenges, including high treatment costs, adverse effects associated with current therapies, and limited awareness in developing areas. Additionally, constrained R&D investments due to a smaller patient population may hinder widespread adoption of tardive dyskinesia treatments in the future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Tardive Dyskinesia Treatment Market Segments Analysis
Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Tardive Dyskinesia Treatment Market
The global tardive dyskinesia (TD) treatment market is significantly driven by the supportive actions of regulatory bodies like the U.S. Food and Drug Administration (FDA), which have implemented expedited approval pathways for TD therapies in acknowledgment of the critical unmet medical needs. These initiatives, including fast-track designations and priority reviews, allow for a swifter market introduction of innovative treatments. This regulatory backing not only encourages pharmaceutical companies to focus their investments on developing medications for TD but also positively influences the overall outlook of the global tardive dyskinesia treatment market, fostering advancements in effective therapeutic options for patients.
Restraints in the Global Tardive Dyskinesia Treatment Market
The Global Tardive Dyskinesia Treatment market faces several constraints that hinder its growth potential. Despite the advancements brought by VMAT2 inhibitors in managing tardive dyskinesia (TD), these treatments are accompanied by adverse effects such as fatigue, depression, and somnolence, which can negatively influence patient adherence and overall quality of life. Consequently, some patients may choose to discontinue their treatment due to these side effects. Furthermore, apprehensions regarding the long-term safety profiles of these medications could lead healthcare providers to be cautious in prescribing them, ultimately slowing the widespread adoption of effective tardive dyskinesia therapies in the market.
Market Trends of the Global Tardive Dyskinesia Treatment Market
The Global Tardive Dyskinesia Treatment market is witnessing a significant trend towards advanced VMAT2 inhibitor therapies, which have transformed the therapeutic landscape for this condition. Medications like valbenazine (Ingrezza) and deutetrabenazine (Austedo) have gained prominence due to their targeted approach in addressing the underlying mechanisms of tardive dyskinesia, resulting in enhanced efficacy and safety profiles compared to traditional treatments. The introduction of innovative formulations, such as Ingrezza Sprinkle, further supports treatment adherence among patients with swallowing difficulties. As research and development in this area continue to grow, advancements in VMAT2 inhibitors are expected to drive market expansion and shape treatment paradigms in the coming years.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2025-2032)
Market Overview
Medication
Surgery
Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2025-2032)
Market Overview
Antipsychotics
VMAT2 Inhibitors
Botulinum Toxin
Natural Remedies
Dopamine-Depleting Medications
Others
Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2025-2032)
Market Overview
Oral
Injectable
Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2025-2032)
Market Overview
Hospitals
Homecare
Specialty Clinics
Others
Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Others
Global Tardive Dyskinesia Treatment Market Size & CAGR (2025-2032)
North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
US
Canada
Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
